Tremelimumab

monoclonal antibody

Identifier: CI-DRUG-00000611
Entity page: /drug/tremelimumab ↗
Edges: 376

Neighbours: 23 cancers1 genes1 variants10 trials3 approvals
Drawn: 38 of 38 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Tremelimumab approved for …APPROVED_FOR6 of 3
→ approved for	Hepatocellular Carcinomasubtype	supports	FDA ORIG	Hepatocellular Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Lung Non-Small Cell Carcinomasubtype	supports	EMA indication text

Tremelimumab predicts response to …PREDICTS_RESPONSE_TO1 of 1
← predicts response to	High	sensitivity	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →

Tremelimumab predicts response to …PREDICTS_RESPONSE_TO1 of 1

← predicts response to

High

sensitivity

Malignant Colorectal Neoplasm

Curated

Tremelimumab investigated for …INVESTIGATED_FOR15 of 37show all (up to 200)
→ investigated for	Malignant Colorectal Neoplasmsubtype	supports	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Hepatocellular Carcinomasubtype	unknown	4	Hepatocellular Carcinoma	1	Curated	chembl	graph →
→ investigated for	Bladder Neoplasmsubtype	unknown	3	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Lung Small Cell Carcinomasubtype	unknown	3	Lung Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Renal Cell Carcinomasubtype	unknown	3	Renal Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Melanomacancer_family	unknown	3	Melanoma	1	Curated	chembl	graph →
→ investigated for	Squamous Cell Carcinomahistology	unknown	3	Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Bile Duct Neoplasmsubtype	unknown	2	Bile Duct Neoplasm	1	Curated	chembl	graph →
→ investigated for	Female Reproductive System Neoplasmsubtype	unknown	2	Female Reproductive System Neoplasm	1	Curated	chembl	graph →
→ investigated for	Uveal Melanomasubtype	unknown	2	Uveal Melanoma	1	Curated	chembl	graph →
→ investigated for	Head and Neck Squamous Cell Carcinomasubtype	unknown	2	Head and Neck Squamous Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Neoplasmcancer_family	unknown	2	Lung Neoplasm	1	Curated	chembl	graph →
→ investigated for	Dysgerminomahistology	unknown	2	Dysgerminoma	1	Curated	chembl	graph →

Tremelimumab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 140show all (up to 200)
→ investigated in trials for	Hepatocellular Carcinomasubtype 34 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 20 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanomacancer_family 14 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 12 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinomasubtype 8 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Small Cell Carcinomasubtype 7 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasm 7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinomasubtype 7 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Neoplasm 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Biliary Tract Neoplasm 6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Biliary Tract Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Adenocarcinoma 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Mesothelioma 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Mesothelioma	5	Observed	clinicaltrials	graph →

Tremelimumab studied in …STUDIED_INderived10 of 194show all (up to 200)
→ studied in	NCT04988945Phase 2 · active not recruiting TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma · 194 trials list this drug (68 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07391670Phase 1 · recruiting A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab · 194 trials list this drug (68 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06109272Phase 2/Phase 3 · active not recruiting A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) · 194 trials list this drug (68 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03158064Phase 2 · active not recruiting Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors · 194 trials list this drug (68 active)	—	—	Germ Cell Tumor,Germinomatous Germ Cell Tumor,Dysgerminoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT03847649Phase 2 · recruiting A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies · 194 trials list this drug (68 active)	—	—	Malignant Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · 194 trials list this drug (68 active)	—	—	Invasive Bladder Micropapillary Urothelial Carcinoma,Malignant Ureter Neoplasm,Malignant Urethral Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05883644Phase 3 · active not recruiting Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) · 194 trials list this drug (68 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04817826Phase 2 · active not recruiting TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. · 194 trials list this drug (68 active)	—	—	Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02962063Phase 1/Phase 2 · active not recruiting Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer · 194 trials list this drug (68 active)	—	—	Esophageal Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · 194 trials list this drug (68 active)	—	—	Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths